Answers are grounded in this paper and cite their sources.
Early control in the acute phase of hepatitis C infection is an attractive therapeutic goal in order to shorten disease duration and infectivity, to prevent chronicity and progression to advanced liver disease and to avoid eventual therapeutic non-response in the later stages of chronic hepatitis C. Over the past decade, different interferon-based treatment options have been developed, which lead to sustained virological response rates of up to 98%. The present article summarizes the successful invention of immediate and delayed strategies in acute hepatitis C monoinfection, critically discusses potential limitations and illustrates the therapeutic challenges of the near future.
No takes yet. Share an insight, caveat, or question.
Wiegand et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: